RxDoctor Payments Data

Michelle Simpson, NP

Nurse Practitioner · Imlay City, MINPI 1053352120

Payments from drug & device makers

$614in general payments, 2019–2025

Across 17 payments — averaging $36.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$255
  • AstraZeneca$125
  • Neurocrine Biosciences, Inc.$110
  • Lilly USA, LLC$51
  • Dexcom, Inc.$22
  • AbbVie$19
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$614100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$614 in reported general payments places this provider in the 75th percentile of 3,351 nurse practitioner providers in Michigan.

See all nurse practitioner providers in Michigan

Medicare billing

Part B allowed, 2024
$17,864
Medicare patients
92
Services billed
370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$37,752
JardianceEmpagliflozin11$18,224
JanuviaSitagliptin Phosphate12$12,614
Atorvastatin Calcium113$1,779
Estradiol12$1,680
Levothyroxine Sodium84$1,157
Duloxetine Hcl42$947
Rosuvastatin Calcium32$836
Omeprazole48$813
Lisinopril84$764
Venlafaxine Hcl ErVenlafaxine Hcl17$673
Metformin Hcl48$584
Metoprolol Succinate36$577
Pravastatin Sodium30$540
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide17$525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$255$37,75219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,351 nurse practitioner providers in Michigan.

Other nurse practitioner in Imlay City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →